Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Munich - Delayed Quote EUR

Daiichi Sankyo Co Ltd (D4S.MU)

20.55
+0.35
+(1.73%)
As of 10:34:03 AM GMT+2. Market Open.
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,687,028,000
1,601,688,000
1,278,478,000
1,044,892,000
962,516,000
Cost of Revenue
416,696,000
415,322,000
363,525,000
353,400,000
338,289,000
Gross Profit
1,270,332,000
1,186,366,000
914,952,000
691,491,000
624,227,000
Operating Expense
1,009,797,000
974,777,000
794,370,000
618,464,000
560,432,000
Operating Income
260,535,000
211,589,000
120,582,000
73,027,000
63,795,000
Net Non Operating Interest Income Expense
34,526,000
25,461,000
6,293,000
361,000
10,161,000
Pretax Income
295,299,000
237,234,000
126,854,000
73,516,000
74,124,000
Tax Provision
65,911,000
36,217,000
17,666,000
6,543,000
-1,705,000
Net Income Common Stockholders
229,101,000
200,731,000
109,188,000
66,972,000
75,958,000
Diluted NI Available to Com Stockholders
229,101,000
200,731,000
109,188,000
66,972,000
75,958,000
Basic EPS
119.55
104.69
56.95
34.94
39.17
Diluted EPS
119.47
104.62
56.91
34.91
39.11
Basic Average Shares
1,916,694.30
1,917,384.66
1,917,034.61
1,916,602
1,939,343
Diluted Average Shares
1,917,928.41
1,918,667.56
1,918,587
1,918,499
1,941,975
Total Operating Income as Reported
260,535,000
211,588,000
120,580,000
73,025,000
63,795,000
Total Expenses
1,426,493,000
1,390,099,000
1,157,895,000
971,864,000
898,721,000
Net Income from Continuing & Discontinued Operation
229,101,000
200,731,000
109,188,000
66,972,000
75,958,000
Normalized Income
229,101,000
200,731,000
109,188,000
66,972,000
75,958,000
Interest Income
41,799,000
31,487,000
14,773,000
6,114,000
12,916,000
Interest Expense
7,273,000
6,026,000
8,480,000
5,753,000
2,755,000
Net Interest Income
34,526,000
25,461,000
6,293,000
361,000
10,161,000
EBIT
302,572,000
243,260,000
135,334,000
79,269,000
76,879,000
EBITDA
364,664,000
302,906,000
203,123,000
137,514,000
134,261,000
Reconciled Cost of Revenue
416,696,000
415,322,000
363,525,000
353,400,000
338,289,000
Reconciled Depreciation
62,092,000
59,646,000
67,789,000
58,245,000
57,382,000
Net Income from Continuing Operation Net Minority Interest
229,101,000
200,731,000
109,188,000
66,972,000
75,958,000
Normalized EBITDA
364,664,000
302,906,000
203,123,000
137,514,000
134,261,000
Tax Rate for Calcs
0
0
0
0
0
3/31/2021 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMGN.MX Amgen Inc.
5,500.00
0.00%
 
4AB.F AbbVie Inc.
155.80
+0.65%
 
OPHLY Ono Pharmaceutical Co., Ltd.
4.1500
+5.87%
 
PNVL3.SA Dimed S.A. Distribuidora de Medicamentos
8.71
-0.68%
 
ORNBVh.XC
 
NOV.MU Novo Nordisk A/S
54.09
-0.64%
 
GRF-P.MC Grifols SA
6.35
-0.78%
 
0R34.IL Johnson & Johnson
155.78
-1.34%
 
GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited
2,916.75
+2.31%
 
NOTA.DU Novartis AG
97.60
+0.62%